These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22771133)

  • 41. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
    Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
    Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
    Curtis JR; Jain A; Askling J; Bridges SL; Carmona L; Dixon W; Finckh A; Hyrich K; Greenberg JD; Kremer J; Listing J; Michaud K; Mikuls T; Shadick N; Solomon DH; Weinblatt ME; Wolfe F; Zink A
    Semin Arthritis Rheum; 2010 Aug; 40(1):2-14.e1. PubMed ID: 20674669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
    Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RAISE - rheumatoid arthritis independent Swiss treatment expectations and outcome: results for the abatacept subpopulation.
    Dudler J; Tuerk R; Handschin T; Forster A
    Swiss Med Wkly; 2013; 143():w13849. PubMed ID: 24318979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
    Boubouchairopoulou N; Flouri I; Drosos AA; Boki K; Settas L; Zisopoulos D; Skopouli FN; Papadopoulos I; Iliopoulos A; Kyriopoulos J; Boumpas DT; Athanasakis K; Sidiropoulos P
    Clin Exp Rheumatol; 2016; 34(6):999-1005. PubMed ID: 27749220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
    Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Askling J; Neovius M;
    Rheumatology (Oxford); 2015 Aug; 54(8):1472-7. PubMed ID: 25796560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
    Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variation in the use of biologics in the management of rheumatoid arthritis across the UK.
    Choy E; Taylor P; McAuliffe S; Roberts K; Sargeant I
    Curr Med Res Opin; 2012 Oct; 28(10):1733-41. PubMed ID: 22978773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.
    Kojima T; Kaneko A; Hirano Y; Ishikawa H; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Terabe K; Fukaya N; Kanayama Y; Shioura T; Funahashi K; Hayashi M; Kato D; Matsubara H; Fujibayashi T; Kojima M; Ishiguro N;
    Mod Rheumatol; 2012 Jun; 22(3):339-45. PubMed ID: 21892671
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.
    Kawashima H; Kagami SI; Kashiwakuma D; Takahashi K; Yokota M; Furuta S; Iwamoto I
    Rheumatol Int; 2017 Mar; 37(3):369-376. PubMed ID: 27999943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems.
    Kerr GS; Swearingen C; Mikuls TR; Yazici Y
    J Clin Rheumatol; 2017 Jan; 23(1):12-18. PubMed ID: 28002151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
    Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
    Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
    Söderlin MK; Lindroth Y; Turesson C; Jacobsson LT
    Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of a rehabilitative programme in improving fatigue and function in rheumatoid arthritis patients treated with biologics: a pilot study.
    Di Gioia L; Zincarelli C; Di Minno MN; Rengo G; Peluso R; Spanò A; Iervolino S; Pappone N
    Clin Exp Rheumatol; 2013; 31(2):285-8. PubMed ID: 23406843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.